RecruitingPhase 2NCT06812390

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Albumin Assisted Diuresis in Patients with Cirrhosis Decompensated by Ascites and Peripheral Edema, a Proof-of-concept Double Blind Randomized Trial

Sponsor

Anahita Rabiee MD MHS

Enrollment

20 participants

Start Date

Feb 28, 2025

Study Type

INTERVENTIONAL

Conditions

Cirrhosis Ascites Hepatic

Summary

A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Albumin infusion (25% albumin) and a drug called Normal Saline (0.9% NaCl) for people with ascites hepatic and cirrhosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.